KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Trial details
- Registry ID
- NCT06193889
- Drugs studied
- KYV-101, Standard lymphodepletion regimen, Standard of Care Treatment
TrialRedline tracks 3 clinical trials sponsored by Kyverna Therapeutics: 1 Phase 2 / 3, 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia GravisNCT06193889 | KYV-101, Standard lymphodepletion regimen, Standard of Care Treatment | Recruiting | 2027-09Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple SclerosisNCT06384976 | Anti-CD20 mAB, KYV-101, Standard lymphodepletion regimen | Active not recruiting | 2027-04Estimated |
| KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person SyndromeNCT06588491 | Standard lymphodepletion regimen | Completed | 2026-06-25Actual |
Names as written in the registry records.
Before: Estimated. After: Actual.
Before: 25 participants (planned). After: 27 participants (actual).
Before: Estimated. After: Actual.
Before: Jul 2026. After: 25 Jun 2026.
Before: Active not recruiting. After: Completed.
Before: Apr 2026. After: Jul 2026.
NCT06193889 · Kyverna Therapeutics
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 2) Measure: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline (Phase 2) Measure: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline for KYV-101 Treatment Arm to Standard of Care Arm (Phase 3) Measure: Efficacy of KYV-101 via Quantitative Myasthenia Gravis (QMG) change from baseline for KYV-101 Treatment arm to Standard of Care arm. After: Measure: Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 2) Measure: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline (Phase 2) Measure: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3) Measure: Efficacy of KYV-101 via Quantitative Myasthenia Gravis (QMG) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3).
Before: Recruiting. After: Active not recruiting.